Overview

  • Product nameNiclosamide
  • Description
    Antihelminthic, anticancer and protonophric agent. STAT3 inhibitor.
  • Biological descriptionAntihelminthic, anticancer and protonophric agent. STAT3 inhibitor (IC50 = 0.25 μM). Shown to inhibit a number of downstream signaling pathways including mTORC1, Wnt/β-catinin, NF-κB, notch and ROS.
  • Purity> 95%

Properties

    References for Niclosamide (ab120868)

    This product has been referenced in:
    • Pan JX  et al. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer 31:178-84 (2012). Read more (PubMed: 22237038) »
    • Fonseca BD  et al. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem 287:17530-45 (2012). Read more (PubMed: 22474287) »
    • Lu W  et al. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/ß-catenin pathway. PLoS One 6:e29290 (2011). Read more (PubMed: 22195040) »
    • Jin Y  et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 70:2516-27 (2010). Read more (PubMed: 20215516) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120868.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"